{
  "id": "management-of-the-incidental-renal-mass-on-ct-281966",
  "title": "Management of the Incidental Renal Mass on CT: A White Paper of the ACR Incidental Findings Committee - Journal of the American College of Radiology",
  "source": "Management of the Incidental Renal Mass on CT.html",
  "blocks": [
    {
      "type": "heading",
      "level": 2,
      "text": "Login to your account"
    },
    {
      "type": "paragraph",
      "text": "If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password"
    },
    {
      "type": "paragraph",
      "text": "If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password"
    },
    {
      "type": "table",
      "columns": [
        "Property",
        "Value"
      ],
      "rows": [
        [
          "Status"
        ],
        [
          "Version"
        ],
        [
          "Ad File"
        ],
        [
          "Disable Ads Flag"
        ],
        [
          "Environment"
        ],
        [
          "Moat Init"
        ],
        [
          "Moat Ready"
        ],
        [
          "Contextual Ready"
        ],
        [
          "Contextual URL"
        ],
        [
          "Contextual Initial Segments"
        ],
        [
          "Contextual Used Segments"
        ],
        [
          "AdUnit"
        ],
        [
          "SubAdUnit"
        ],
        [
          "Custom Targeting"
        ],
        [
          "Ad Events"
        ],
        [
          "Invalid Ad Sizes"
        ]
      ]
    },
    {
      "type": "image",
      "assetId": "asset_3f674051e7",
      "alt": "Cover Image - Journal of the American College of Radiology, Volume 15, Issue 2"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Share"
    },
    {
      "type": "list",
      "items": [
        "Email",
        "X",
        "Facebook",
        "LinkedIn",
        "Sina Weibo",
        "Add to Mendeley",
        "bluesky"
      ]
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Share"
    },
    {
      "type": "list",
      "items": [
        "Email",
        "X",
        "Facebook",
        "LinkedIn",
        "Sina Weibo",
        "Add to Mendeley",
        "Bluesky"
      ]
    },
    {
      "type": "list",
      "items": [
        "Download PDFDownload PDF",
        "Cite",
        "Set Alert",
        "Get Rights",
        "Reprints"
      ]
    },
    {
      "type": "paragraph",
      "text": "Download started"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Abstract"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Key Words"
    },
    {
      "type": "list",
      "items": [
        "Kidney",
        "renal",
        "small renal mass",
        "cyst",
        "Bosniak classification",
        "incidental finding"
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Overview of the ACR Incidental Findings Project"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "The Consensus Process: The Incidental Renal Mass Algorithm"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Elements of the Flowcharts: Color-Coding"
    },
    {
      "type": "image",
      "assetId": "asset_938f3f8838",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig 1 Flowchart for managing an incidental renal mass on noncontrast CT. 1If the mass contains fat attenuation (a region of interest < 10 HU), refer to Figure 5. 2Too small to characterize. 3Well-circumscribed and homogeneous TSTC renal masses that are visually much lower or much higher than the unenhanced renal parenchyma are probably benign cystic lesions. 4MRI is preferred for characterizing smaller masses (<1.5 cm) and for detecting enhancement in suspected hypovascular masses. Ultrasound may be able to characterize a homogeneous hyperattenuating renal mass as a hemorrhagic or proteinaceous cyst. 5If old images are available, any renal mass that has been without change in imaging features and has had an average growth of <= 3 mm per year for at least 5 years is likely of no clinical significance and does not need further workup. HU = Hounsfield unit; TSTC = too small to characterize; WO&W = without and with; W/U = work-up."
    },
    {
      "type": "image",
      "assetId": "asset_876348c5a8",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig 2 Flowchart for managing an incidental renal mass on contrast-enhanced CT. 1If the mass contains fat attenuation (a region of interest < 10 HU), refer to Figure 5. 2Too small to characterize. 3Well-circumscribed and homogeneous TSTC renal masses that are visually much lower than the enhanced renal parenchyma are probably benign cystic lesions. 4MRI is preferred for characterizing smaller masses (<1.5 cm) and for detecting enhancement in suspected hypovascular masses. Ultrasound may be able to characterize a homogeneous renal mass as a hemorrhagic or proteinaceous cyst. 5If old images are available, any renal mass that has been without change in imaging features and has had an average growth of <=3 mm per year for at least 5 years is likely of no clinical significance and does not need further workup. HU = Hounsfield unit; TSTC = too small to characterize; WO&W = without and with; W/U = work-up."
    },
    {
      "type": "image",
      "assetId": "asset_8a5737f7f3",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig 3 Flowchart for managing a cystic renal mass on CT or MRI performed both without and with IV contrast. 1If the mass contains fat attenuation (a region of interest < 10 HU), refer to Figure 5. 2Morphologic change includes increasing number of septa, thickening of the wall or septa, or development of a solid nodular component (including reclassification as Bosniak III or IV). Growth of a cystic mass without morphologic change is not indicative of malignancy. 3A Bosniak IIF cystic renal mass without change in imaging features for at least 5 years is considered stable and likely of no clinical significance. HU = Hounsfield unit; IV = intravenous; WO&W = without and with; W/U = work-up."
    },
    {
      "type": "image",
      "assetId": "asset_7324a0409b",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig 4 Flowchart for managing for a completely characterized solid renal mass or renal mass too small to characterize on CT or MRI performed both without and with IV contrast. 1If the mass contains fat attenuation (a region of interest < 10 HU), refer to Figure 5. 2Too small to characterize. 3Size = largest diameter in any plane, follows TNM version 7 staging criteria. 4Well-circumscribed TSTC renal masses, either calcified or noncalcified but that are otherwise homogeneous and either visually much lower than the renal parenchyma on any phase or much higher than the unenhanced renal parenchyma, are probably benign cystic lesions that do not need further evaluation. 5MRI is preferred for characterizing smaller renal masses (<1.5 cm) and for detecting enhancement in suspected hypovascular masses. 6A renal mass without change in imaging features and with an average growth of <=3 mm per year for at least 5 years is considered stable and likely of no clinical significance. 7Growth is defined as >=4 mm per year average; morphologic change is any change in heterogeneity, such as a change in contour, attenuation, or number of septa. 8Consider biopsy, especially if hyperattenuating on unenhanced CT, or hypointense on T2WI MRI, because these are suggestive of a fat-poor angiomyolipoma. 9If a pathologic diagnosis is desired to determine management but biopsy is technically challenging, or there is another relative contraindication to biopsy, consider MRI to assess the signal intensity on T2WI. Fat-poor angiomyolipoma and papillary renal cell carcinoma may be hypointense on T2WI in contrast to clear cell renal cell carcinoma, which is typically heterogeneous and mildly hyperintense on T2WI. HU = Hounsfield unit; IV = intravenous; T2WI = T2-weighted imaging; WO&W = without and with; W/U = work-up."
    },
    {
      "type": "image",
      "assetId": "asset_3fa3b15cf8",
      "alt": ""
    },
    {
      "type": "paragraph",
      "text": "Fig 5 Flowchart for managing an incidental renal mass with a region of interest measuring fat attenuation (less than 10 HU). 1Incidental sporadic AML (ie, no hematuria, flank pain, or perilesional hemorrhage.) 2Many urologists will follow patients with small AMLs that are rapidly growing and some patients with multiple AMLs may benefit from an evaluation for tuberous sclerosis complex. 3If only an unenhanced CT has been performed, consider CT or MR without and with IV contrast. 4Patients with symptomatic AMLs (hematuria, flank pain, spontaneous bleeding) should be referred to urology regardless of size. 5AML >= 4 cm or those with aneurysms greater than 0.5 cm should be referred for prophylactic treatment. AML = angiomyolipoma; HU = Hounsfield unit; IV = intravenous; WO&W = without and with; W/U = work-up."
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Nature and Scope of the Problem"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Definition of the Incidental Renal Mass"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Treatment Recommendations"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Factors That May Affect the Management of Renal Masses"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Reporting Considerations"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "1 Size"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "2 to 4 Attenuation, Homogeneity Versus Heterogeneity, and Enhancement"
    },
    {
      "type": "table",
      "columns": [
        "Feature"
      ],
      "rows": [
        [
          "Wall thickening"
        ],
        [
          "One or more septa"
        ],
        [
          "Mural nodule(s)"
        ],
        [
          "Measurable or visible attenuation differences"
        ],
        [
          "Calcification"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "Bosniak Classification",
        "Description"
      ],
      "rows": [
        [
          "I",
          "Benign simple cyst with a hairline thin wall without septa, calcification, or solid component. Homogeneous near-water attenuation density (10 to 20 HU) without enhancement."
        ],
        [
          "II",
          "Benign minimally complicated cyst that may contain a few hairline thin septa that may have perceived but not measurable enhancement. Fine calcification or a segment of slightly thickened calcification may be present in the wall or septa. Also, a well-marginated nonenhancing homogeneous mass < 3 cm with density above simple fluid attenuation (hyperdense cyst)."
        ],
        [
          "IIF",
          "Usually benign complicated renal cyst with multiple hairline thin septa or minimal smooth thickening of the wall or septa. Wall or septa may contain thick and nodular calcification and may have perceived but not measurable enhancement. Also, a well-marginated intrarenal nonenhancing mass > 3 cm with density above simple fluid."
        ],
        [
          "III",
          "Indeterminate complicated cystic renal mass with thickened irregular walls or septa that have measurable enhancement."
        ],
        [
          "IV",
          "Malignant cystic renal mass with enhancing soft tissue components (cystic renal cell carcinoma)."
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "table",
      "columns": [
        "CT Criteria: Increase in Attenuation After Contrast"
      ],
      "rows": [
        [
          ">=20 HU",
          "Definite for enhancement"
        ],
        [
          ">10 to < 20 HU",
          "Equivocal for enhancement; consider factors related to beam hardening, intra-renal location"
        ],
        [
          "<=10 HU",
          "No enhancement"
        ]
      ]
    },
    {
      "type": "table",
      "columns": [
        "MRI criteria for enhancement"
      ],
      "rows": [
        [
          ">=15% increase in signal intensity after contrast",
          "Enhancing lesion"
        ],
        [
          "Alternative method",
          "Visible signal intensity on subtraction images"
        ]
      ]
    },
    {
      "type": "list",
      "items": [
        "Open table in a new tab"
      ]
    },
    {
      "type": "heading",
      "level": 3,
      "text": "5 Complexity of Cystic Masses (Bosniak Classification)"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "6 Growth and Morphologic Change"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "7 Role of Biopsy"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Inclusion and Exclusion Criteria for Use of the Algorithm"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Implications of Imaging and Clinical Features"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Basic Principles of the Algorithm"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Overview of the Algorithm"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Flowchart 1: Incidental Renal Mass on Unenhanced CT"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Flowchart 2: Incidental Renal Mass on Contrast-Enhanced CT"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Flowchart 3: Cystic Renal Mass on CT or MRI Without and With IV Contrast"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Flowchart 4: Solid Renal Masses and Masses TSTC on CT or MRI Without and With IV Contrast"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Flowchart 5: Renal Masses Containing Fat Attenuation"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Imaging Options"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Primary options: MR and CT"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Newer Technologies and Other Modalities"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Take-Home Points"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Acknowledgments"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Additional Resources"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Figures (5)Figure Viewer"
    },
    {
      "type": "image",
      "assetId": "asset_938f3f8838",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_876348c5a8",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_8a5737f7f3",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_7324a0409b",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_3fa3b15cf8",
      "alt": ""
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Article metrics"
    },
    {
      "type": "image",
      "assetId": "asset_b403fc5f11",
      "alt": "Plum X logo"
    },
    {
      "type": "list",
      "items": [
        "207 Citations 186 Captures 1 Mentions 16 Social Media View details opens in a new tab"
      ]
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Related articles (40)"
    },
    {
      "type": "list",
      "items": [
        "Patel et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Berland et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Khosa et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Patel et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Gore et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Sebastian et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Heller et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Mayo-Smith et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Hoang et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Munden et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Megibow et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Munden et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Hoang et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Moonis et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Berland et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Abu-Yousef et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Lee et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Lincoln L. Berland"
      ]
    },
    {
      "type": "list",
      "items": [
        "Paulson et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Samim et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Moore et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Dyer et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Johnson et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Lincoln L. Berland"
      ]
    },
    {
      "type": "list",
      "items": [
        "Bobbin et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Kang et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Crable et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Lehnert et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "McFarland et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Verdini et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Kang et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Tessler et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Stephen D. Brown"
      ]
    },
    {
      "type": "list",
      "items": [
        "Zygmont et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Kapoor et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Nguyen et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Baccei et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Shah et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Borra et al."
      ]
    },
    {
      "type": "list",
      "items": [
        "Andreotti et al."
      ]
    },
    {
      "type": "image",
      "assetId": "asset_938f3f8838",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_876348c5a8",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_8a5737f7f3",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_7324a0409b",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_3fa3b15cf8",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_938f3f8838",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_876348c5a8",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_8a5737f7f3",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_7324a0409b",
      "alt": ""
    },
    {
      "type": "image",
      "assetId": "asset_3fa3b15cf8",
      "alt": ""
    },
    {
      "type": "list",
      "items": [
        "Fig 1",
        "Fig 2",
        "Fig 3",
        "Fig 4",
        "Fig 5"
      ]
    },
    {
      "type": "list",
      "items": [
        "Download .PPT"
      ]
    },
    {
      "type": "paragraph",
      "text": "The content on this site is intended for healthcare professionals."
    },
    {
      "type": "list",
      "items": [
        "Privacy Policy",
        "Terms and Conditions",
        "Accessibility",
        "Help & Contact"
      ]
    },
    {
      "type": "image",
      "assetId": "asset_126f4c2977",
      "alt": "RELX"
    },
    {
      "type": "image",
      "assetId": "asset_305aabbb5b",
      "alt": "Company Logo"
    },
    {
      "type": "heading",
      "level": 2,
      "text": "Cookie Preference Center"
    },
    {
      "type": "image",
      "assetId": "asset_a70415f05d",
      "alt": "Cookie Settings | Your Privacy Choices"
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Manage Consent Preferences"
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Strictly Necessary Cookies"
    },
    {
      "type": "paragraph",
      "text": "These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Functional Cookies"
    },
    {
      "type": "paragraph",
      "text": "These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Performance Cookies"
    },
    {
      "type": "paragraph",
      "text": "These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site."
    },
    {
      "type": "heading",
      "level": 4,
      "text": "Targeting Cookies"
    },
    {
      "type": "paragraph",
      "text": "These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. If you do not allow these cookies, you will experience less targeted advertising."
    },
    {
      "type": "heading",
      "level": 3,
      "text": "Cookie List"
    },
    {
      "type": "image",
      "assetId": "asset_7d8b03fc40",
      "alt": "Powered by Onetrust"
    }
  ]
}
